Artios Pharma Strengthens Clinical Development Team with Senior Appointments

CAMBRIDGE, UK and NEW YORK, USA, 10 February 2020 Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Bryony Harrop as Vice President (VP) of Clinical Development,  Bryony will be working alongside Dr Gillian Langford, also VP of Clinical Development, who joined Artios in January 2019.

Bryony will report directly to Chief Medical Officer, Dr Ian Smith, and in collaboration with Gillian will be responsible for the clinical development strategy, regulatory, and medical activities of Artios’ medicines that target aspects of DNA Damage Response (DDR), including inhibitors of DNA Polymerase Theta and Ataxia-Telangiectasia and Rad3 – related protein kinase (ATR) programmes.

Read more…………

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH